Avalon Ventures Gets Exit At Sitari Pharmaceuticals
socalTECH
SEPTEMBER 11, 2019
San Diego-based biotech investor Avalon Ventures has scored an exit, saying late Tuesday evening that it has entered into a definitive agreement with GlaxoSmithKline (GSK), to sell Sitari Pharmaceuticals to GSK. Sitari was developing treatments for celiac disease, and was being incubated at COI Pharmaceuticals.
100 
Let's personalize your content